Pattern of Proliferative Index (Ki-67) after Anti-Androgen Manipulation Reflects the Ability of Irradiation to Control Prostate Cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 27, Issue 1, 2004, Pages 85-88

  Hintz, Brace L ^a,b   Koo, Charles ^a   Murphy, James F ^a  

^a KAISER PERMANENTE   (United States)

^b NONE   (United States)

Author keywords

Antiandrogen therapy; Irradiation; Ki 67; Prostate cancer

Indexed keywords

ANTIANDROGEN; KI 67 ANTIGEN; LEUPRORELIN; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; APOPTOSIS; ARTICLE; BEAM THERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CELL CYCLE; CELL KILLING; CLINICAL ARTICLE; DNA STRAND BREAKAGE; DRUG WITHDRAWAL; HORMONE SENSITIVITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE BIOPSY; PROSTATE CANCER; RADIATION DOSE; SIDE EFFECT;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BIOPSY; CELL CYCLE; HUMANS; KI-67 ANTIGEN; LEUPROLIDE; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PILOT PROJECTS; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE;

EID: 0842284010     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000046302.23399.F3     Document Type: Article

References (12)

1. Wazer DE, Tercilla OF, Lin P-S, et al. Modification in the radiosensitivity of MCF-7 human carcinoma cells by 17B-estradiol & tamoxifen. Br J Radiol 1989;62:1079-83.
2. Sutherland RL, Reddel RR, Taylor IW. Effects of Tamoxifen and its metabolites on breast cancer cell proliferation hereditary in vitro. Rev Endocr Rel Cancer 1986;suppl 19:5-13.
3. Scott RJ, Hall PA, Haldane JS, et al. A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth faction. J Pathol 1991;165:173-8.
4. Hsu SM, Raive L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase technique: a comparison between ABC and unlabeled antibody procedures. J Histochem Cytochem 1981;29:577-80.
5. Zagars G, Johnson DE, Von Eschenbach AC, et al. Adjuvant estrogen following radiation therapy for stage C of the prostate; long-term results of prospective randomized study. Int J Radiat Oncol Biol Phys 1998;14:1085-91.
6. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen using Goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy. Report of RTOG Protocol 85-31. J Clin Oncol 1997;15:1013-21.
7. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and Goserelin. N Engl J Med 1997;337:295-300.
8. Laverdiere J, Labrie F, Gomez J. Beneficial effect of combination hormonal therapy administered prior to and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997;37:247-52.
9. Lawton CA, Winter K, Murray K, et al. Updated results of the phase III RTOG 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for the unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49:937-46.
10. Horwitz EM, Winter K, Hanks GE, et al. Subset analysis of RTOG-85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormone for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 2001;49:947-56.
11. Joon DL, Hasegawa M, Sikes C, et al. Supraadditive response of R3327-G rat prostate tumor to androgen ablation and radiation. Int J Radiat Oncol Biol Phys 1997;38:1071-7.
12. Shen K-L, Ham H-J, Ho L-I, et al. The extent of proliferative and apoptotic activity in intraductal and invasive ductal breast carcinoma detected by Ki-67 labeling a terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick-end labeling. Cancer 1998;82:2373-81.